MOSCOW (Sputnik) - The efficacy of Russia's Sputnik V coronavirus vaccine is 91.4 percent, based on a second interim analysis of data obtained 28 days after the injection of the first dose of the two-component vaccine, the Russian Direct Investment Fund (RDIF) said on Tuesday.
As many as 22,000 volunteers have already received the first dose of the vaccine, while over 19,000 volunteers have received the first and the second doses, according to the RDIF. A total of 40,000 volunteers are taking part in the phase 3 clinical post-registration trials.
"Evaluation of efficacy was carried out among volunteers (n = 18,794) 28 days after receiving the first dose (7 days after the second dose) of the vaccine or placebo upon reaching the second check point of the trial in compliance with the clinical trial protocol. The analysis demonstrated a 91.4% efficacy rate for the Sputnik V vaccine", the RDIF said in a press release, published on the official Twitter account of the vaccine.
Preliminary data obtained on the 42nd day after receiving the first dose of the vaccine, when the volunteers had already formed a stable immune response, "indicates the efficacy rate of the vaccine is above 95%", the RDIF specified.
"We plan to conduct the third interim data analysis after 78 confirmed coronavirus cases among volunteers and we have every reason to believe that the results will exceed our initial expectations. The drug’s final efficacy assessment will be made available after Phase III clinical trials are concluded", Alexander Gintsburg, head of the Gamaleya Research Centre that developed the vaccine, said.